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Fasting has been used to control epilepsy since
antiquity, but the mechanism of coupling between
metabolic state and excitatory neurotransmission
remains unknown. Previous work has shown that
the vesicular glutamate transporters (VGLUTs)
required for exocytotic release of glutamate undergo
an unusual formof regulation byCl. Using functional
reconstitution of the purified VGLUTs into proteolipo-
somes, we now show that Cl acts as an allosteric
activator, and the ketone bodies that increase with
fasting inhibit glutamate release by competing with
Cl at the site of allosteric regulation. Consistent
with these observations, acetoacetate reduced
quantal size at hippocampal synapses and
suppresses glutamate release and seizures evoked
with 4-aminopyridine in the brain. The results indi-
cate an unsuspected link between metabolic state
and excitatory neurotransmission through anion-
dependent regulation of VGLUT activity.INTRODUCTION
Epilepsy is a common neurological disorder affecting1%of the
population worldwide. Although a large number of drugs have
been developed to treat seizures (Meldrum and Rogawski,
2007), approximately one-third of epileptic patients remain
poorly controlled, and many continue to rely on fasting or
a high-fat, low-protein and -carbohydrate (‘ketogenic’) diet orig-
inally described in biblical times (Laffel, 1999; Vining, 1999;
Bailey et al., 2005; Zupec-Kania and Spellman, 2008). Through
b-oxidation in the liver, fasting and the ketogenic diet produce
ketone bodies, in particular acetoacetate and b-hydroxybuty-
rate, and these circulating metabolites enter the brain where
they serve as substrates for energy production in neurons (Laffel,1999; Freeman et al., 2006; Hartman et al., 2007). Under normal
circumstances, the blood level of ketone bodies is maintained
at 0.3 mM but increases markedly up to 10 mM with a keto-
genic diet (Laffel, 1999; Freeman et al., 2006; Bough and Rho,
2007). Ketone bodies are thus considered to be responsible for
the therapeutic effect of fasting and the ketogenic diet (Freeman
et al., 2006; Bough and Rho, 2007; Hartman et al., 2007).
How do ketone bodies control epilepsy? They might suppress
excitatory neurotransmission and/or stimulate inhibitory neuro-
transmission (Nordli and De Vivo, 1997; Freeman et al., 2006;
Bough and Rho, 2007; Hartman et al., 2007; Yudkoff et al.,
2008). However, the effects on brain glutamate and GABA
content remain controversial, and systemic levels of glutamate
and GABA do not significantly change with a ketogenic diet
(Appleton and DeVivo, 1974; Bough and Rho, 2007; Hartman
et al., 2007; Yudkoff et al., 2008). The expression and activity
of receptors and plasma membrane transporters for glutamate
and GABA also do not change (Thio et al., 2000; Noh et al.,
2004; Bough et al., 2007; Hartman et al., 2007). Recent work
has suggested that acetoacetate reduces firing by lowering
cytoplasmic ATP, thereby activating the ATP-sensitive K+
channel (KATP) (Ma et al., 2007). However, the effect on KATP
has not been tested in vivo, and the effect of ketone bodies on
cytoplamic ATP remains controversial (Nakazawa et al., 1983;
Zhao et al., 2006).
The filling of synaptic vesicles with glutamate has a crucial role
in glutamatergic neurotransmission and depends on the activity
of the vesicular glutamate transporters (VGLUT1–3) (Reimer, and
Edwards, 2004, Fremeau et al., 2004a; Edwards 2007). The
VGLUTs use a membrane potential (Dc) established by the
vacuolar proton pump (V-ATPase) as a driving force (Maycox
et al., 1988; Moriyama and Yamamoto, 1995; Juge et al.,
2006). The loss of VGLUT activity eliminates vesicular release
and glutamatergic neurotransmission, with profound conse-
quences for behavior and indeed survival, indicating the essen-
tial role(s) of VGLUTs in brain function (Fremeau et al., 2004b;
Wojcik et al., 2004; Moechars et al., 2006; Walle´n-Mackenzie
et al., 2006; Smear et al., 2007; Gras et al., 2008; Seal et al.,
2008, 2009).Neuron 68, 99–112, October 7, 2010 ª2010 Elsevier Inc. 99
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Metabolic Control of Excitatory NeurotransmissionOne of the most unusual but unexplained features of VGLUT
function is its Cl dependence. ATP-dependent glutamate
uptake in synaptic vesicles exhibits a biphasic dependence on
Cl (Naito and Ueda, 1985; Maycox et al., 1988; Moriyama and
Yamamoto, 1995). In the absence of Cl, glutamate uptake
into synaptic vesicles is very low, but low [Cl] (4 mM) strongly
activates transport, with inhibition at higher concentrations. Cl
dependence is even more extreme in proteoliposomes contain-
ing purified VGLUT2 and bacterial F-ATPase; no transport
activity is observed in the absence of Cl but full activity
appears 4 mM Cl (Juge et al., 2006). It has been proposed
that the Cl dependence on the glutamate uptake reflects an
allosteric effect, and that the decrease at high [Cl] reflects dissi-
pation of Dc (Hartinger and Jahn, 1993; Moriyama and Yama-
moto, 1995; Juge et al., 2006). However, previous work using
heterologous expression has suggested that VGLUT1 exhibits
a Cl conductance (Bellocchio et al., 2000), and more recently,
functional reconstitution of purified VGLUT1 and bacterial F-AT-
Pase has supported this possibility, although Cl flux itself was
not actually demonstrated (Schenck et al., 2009). These studies
nonetheless indicate that Cl dependence is an intrinsic property
of VGLUTs, although the mechanism responsible and its
physiological role in the regulation of quantal size remain poorly
understood.
We have investigated the molecular mechanism for regulation
of the VGLUTs by Cl. In the course of these studies, we have
found a surprising but strong link between the Cl dependence
of VGLUTs and the metabolic control of seizures by ketone
bodies. We show that Cl acts as an allosteric activator for
VGLUTs, that ketone bodies and acetoacetate in particular
compete with Cl for VGLUT activation, and that this regulatory
mechanism is conserved in the entire SLC17 transporter family.
Finally, we show that acetoacetate reversibly inhibits glutamate
release in vivo.
RESULTS
Cl– Directly Activates VGLUT2
In both native membranes and proteoliposomes containing an
active proton pump as well as VGLUT, Cl has a dual role in
regulation of the transporter, and in expression of the Dc that
drives transport (Juge et al., 2006; Schenck et al., 2009). To char-
acterize the effect of Cl on the transporter independent of the
driving force, we have therefore established an in vitro assay
with proteoliposomes containing only the purified VGLUTs,
where Cl can be manipulated without affecting Dc.
As a first step to characterizing the interaction of VGLUTs with
Cl, purified VGLUT2 was reconstituted into liposomes in the
presence of Na-acetate (Figure 1A). The resultant proteolipo-
somes were suspended in buffer containing K-acetate. Upon
addition of valinomycin (Val), a stable, inside positive Dc of
87.2 ± 0.07 mV, n = 3, was established through the electrogenic
entry of K+ into proteoliposomes and thus triggered glutamate
uptake (Figure 1B). The characteristics of Val-evoked glutamate
uptake, including the kinetic parameters, sensitivity to Evans
blue and diisothiocyanostilbene disulfonic acid (DIDS), and
insensitivity to aspartate, were essentially identical to those re-
ported previously (Figure 1B and see Figure S1 available online;100 Neuron 68, 99–112, October 7, 2010 ª2010 Elsevier Inc.Juge et al., 2006). Bioenergetic analysis under defined Dc and/
or DpH conditions indicated that Dc but not DpH primarily trig-
gered glutamate uptake (Figure 1C). As observed in proteolipo-
somes containing VGLUT2 and F-ATPase (Juge et al., 2006;
Schenck et al., 2009), Dc-mediated glutamate uptake absolutely
required Cl: glutamate transport was not detected in the
absence of Cl. Glutamate uptake appeared at 2 mM Cl,
increased drastically with a slight increase of [Cl], and reached
a plateau at 5 mM (Figure 1D). The steady glutamate uptake and
magnitude of Dc at Cl concentrations above 5 mM contrasted
with the results of proteoliposomes containing VGLUT and
F-ATPase (Juge et al., 2006; Schenck et al., 2009). It is note-
worthy that Cl-dependent activation of VGLUT2 exhibited
a strong and extraordinarily positive cooperativity for glutamate
transport with a Hill coefficient for Cl of 3 (Figure 1D). We
further found that, in contrast to proteoliposomes containing
VGLUT1 and F-ATPase (Schenck et al., 2009), intravesicular
Cl did not affect Cl and Dc-dependent glutamate uptake
(Figure 1E). Br compensated for Cl, while sulfate showed
a slight stimulatory effect and neither iodide nor fluoride showed
much stimulation (Figure 1F).
VGLUT2 Does Not Transport Cl–
An important question was whether Clwas actually transported
through VGLUT2 during Cl and Dc-dependent glutamate
uptake.We investigated this issue using two independent proce-
dures: direct isotope tracing and a fluorometric procedure
employing 6-methoxy-N-(3-sulfopropyl)-quinolinum monohy-
drate (SPQ), a fluorescent Cl indicator (Biwersi et al., 1994).
The background level of 36Cl uptake was shown in liposomes
in the presence or absence of Dc by radioisotope tracing
(Figure 2A, left). 36Cl uptake at equilibrium was determined by
the addition of nystatin, an anion ionophore (Russell et al.,
1977), to demonstrate the impermeability of the liposomal
membrane to Cl (Figure 2A). Dc alone did not facilitate 36Cl
uptake by VGLUT2-containing proteoliposomes. The inward
flux of Cl during glutamate uptake was significantly lower
than the influx at equilibrium in the presence of nystatin
(Figure 2A). Vesicular GABA transporter (VGAT) is a Dc-driven
Cl/GABA cotransporter and was used as a positive control for
vesicular Cl uptake (Juge et al., 2009). As shown in Figure 2A,
VGAT facilitates active transport of GABA-dependent Cl uptake
against a Cl concentration gradient.
Entry of Cl into proteoliposomes loaded with SPQ should
result in decreased fluorescence intensity due to collisions
between SPQ and Cl (Accardi and Miller, 2004). Therefore,
we prepared SPQ-trapped proteoliposomes and monitored
changes of SPQ fluorescent intensity. SPQ fluorescence
quenching was not observed in the absence or presence of
external Cl (10 mM) in VGLUT2-containing proteoliposomes
(Figure 2B). On the other hand, in VGAT-containing proteolipo-
somes, the addition of GABA and Val quenched SPQ fluores-
cence (Figure 2B). Glycine, another substrate for VGAT
(Juge et al., 2009), caused similar fluorescence quenching, while
glutamate, which is not a substrate for VGAT, did not (Figure 2B).
The addition of Val and GABA to liposomes containing the inac-
tive mutant of VGAT, E213A (Juge et al., 2009), did not quench
SPQ fluorescence (Figure 2B). The quenching induced by Cl,
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Figure 1. Cl– Activates VGLUT2 Externally
(A) Simple assay system for VGLUT. Proteoliposomes containing purified VGLUT2 (10 mg protein) were analyzed in an 11% polyacrylamide gel in the presence of
SDS and visualized by Coomassie brilliant blue staining. The positions of molecular markers are indicated. The principle of Val-evoked glutamate uptake is also
shown.
(B) Time course of glutamate uptake by reconstituted VGLUT2wasmeasured as described in Experimental Procedures in the presence (closed circle) or absence
(open circle) of Val. Kinetics of Val-evoked glutamate uptake at 1 min is shown in the inset. See also Figure S1.
(C) Energetics of glutamate uptake. Glutamate uptake was measured under the indicated ionic conditions. Nig, nigericin.
(D) Concentration dependence of Cl on glutamate uptake. A sample was taken after 1 min. Dc, measured as oxonol-V fluorescence quenching, is shown.
The inset shows the Hill plot of glutamate uptake as a function of [Cl].
(E) Effect of internal and external Cl on glutamate uptake. Proteoliposomes were prepared at the indicated concentrations of Cl and suspended in buffer con-
taining the indicated Cl concentration. Val-evoked glutamate uptake was measured at 1 min.
(F) Cl was replaced with the indicated anion and Val-evoked uptake of glutamate was measured at 1 min. Error bars represent mean ± SEM; n = 3.
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Metabolic Control of Excitatory NeurotransmissionGABA, and Val in VGAT-containing liposomes exhibited dose
dependence with apparent Km values for GABA and Cl
 of
0.79 and 2.7 mM, respectively, while no such dependence was
observed in VGLUT2-containing proteoliposomes (Figure S2).
Acetoacetate Is an Allosteric Modulator of VGLUT2 Cl–
Dependence
The results suggest that Cl acts in an allosteric manner to regu-
late VGLUT activity. If this were the case, other substancesmight
also bind at the same site and affect VGLUT2 Cl-dependence.
We thus screened for such substances and included 10 mM Cl
in the standard assay because this concentration both approxi-
mates physiological conditions and confers maximal activity
(Figure 1D). Among more than 30 metabolic intermediates
tested, we found that ketone bodies (acetoacetate and 3-hy-
droxybutyrate) inhibited glutamate transport (Figures 3Aand S3). In addition, pyruvate, an intermediate in the glycolytic
pathway also inhibited glutamate transport (Figures 3A, S3,
and S4). Of the compounds tested, acetoacetate had the stron-
gest inhibitory effect, exhibiting a half maximal inhibitory concen-
tration (IC50) of 0.2 mM (Figure 3A). The presence of 10 mM
acetoacetate did not affect the formation of Dc by the proteoli-
posomes, confirming that a constant force was established
during the assay (Figure 3B).
As expected, acetoacetate changed the Cl dependence of
VGLUT2, shifting it to higher concentrations (Figure 3C) and
suggesting a competitive interaction. In 10 mM Cl, 1 mM ace-
toacetate inhibited glutamate uptake without affecting the coop-
erativity for Cl (Figure 3D). The effect of 1mM acetoacetate was
overcome by 100 mM Cl (Figure 3C). In contrast, acetoacetate
did not compete with glutamate (Figure 3E). The effect of acetoa-
cetate was totally reversible and full activity was recovered byNeuron 68, 99–112, October 7, 2010 ª2010 Elsevier Inc. 101
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Figure 2. VGLUT2 Does Not Transport Cl– during Glutamate Trans-
port
(A) Uptake of radiolabeled Cl. In the presence of 5 mM glutamate, 36Cl
uptake by liposomes or VGLUT2-containing proteoliposomes was measured
in the presence (+) or absence () of Val. In some experiments, nystatin was
included to estimate [36Cl] at equilibrium. 36Cl uptake by VGAT at 1 min is
shown as a positive control for active Cl transport. Essentially the same
results were obtained when 10% (w/w) cholesterol was included in the proteo-
liposomes. Error bars represent mean ± SEM; n = 3.
(B) Comparison of glutamate or GABA-evoked Cl uptake by VGLUT or VGAT,
respectively, as revealed by SPQ fluorescence. SPQ-trapped VGLUT2-con-
taining proteoliposomes were prepared and SPQ fluorescence intensity was
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102 Neuron 68, 99–112, October 7, 2010 ª2010 Elsevier Inc.washing the compound out of the preparation (Figure 3F).
Furthermore, we found that the effects of Cl and acetoacetate
were observed when these compounds were present outside
vesicles: neither was effective from the luminal side of the
proteoliposomes (Figure 3G). DIDS (1 mM) is a potent inhibitor
for VGLUT but its inhibition was effectively blocked by 100 mM
Cl (Figure 3G; Hartinger and Jahn, 1993; Moriyama and Yama-
moto, 1995; Juge et al., 2006). Similarly, the presence of 5 mM
acetoacetate prevented DIDS-evoked inactivation of VGLUT2
(Figure 3G). Essentially the same effects of Cl and acetoacetate
were observed in the ATP-dependent glutamate uptake by
synaptic vesicles (Figure S5).Other SLC17Members Share the Same Cl– Dependence
So far, six types of vesicular neurotransmitter transporters have
been identified: the VGLUTs, VNUT (vesicular nucleotide
transporter, SLC17A9), VEAT (vesicular excitatory amino acid
transporter, SLC17A5), VGAT (SLC32A1), VMAT1–2 (vesicular
monoamine transporter 1 and 2, SLC18A1–2), and VAChT
(vesicular acetylcholine transporter, SLC18A3) (Schuldiner,
1994; Parsons, 2000; Eiden et al., 2004; Gasnier, 2004; Reimer
and Edwards, 2004; Sawada et al., 2008; Miyaji et al., 2008;
see also Figure S6). Since both Cl dependence and acetoace-
tate sensitivity have been investigated for only VGLUT2, it was
important to determine whether these characteristics were
conserved in other VGLUTs and within the SLC17 family as
a whole. We therefore tested the allosteric activation of these
proteins by Cl and the interaction of Cl with acetoacetate.
VGLUT1, VGLUT3, and VEAT used Dc as a driving force for
transport and absolutely required Cl with a dose-dependence
similar to that of VGLUT2 (Figures 4A–4C). The effect of acetoa-
cetate onDc and Cl-dependent uptake in terms of dose depen-
dence, protection by Cl and reversibility was also similar to that
of VGLUT2 (Figures 4E and S7). No radiolabeled Cl was taken
up by the proteoliposomes during transport of glutamate and
aspartate (Figure 4F). We have already shown that VNUT
requires Cl for transport activity (Sawada et al., 2008). As ex-
pected, Dc and Cl-dependent uptake of ATP by VNUT was
similarly inhibited by acetoacetate (Figure 4E). The inhibitory
effect of acetoacetate was prevented by high concentrations
of Cl and was reversible (Figures 4E and S7). Cl uptake was
also not observed in VNUT (Figure 4F).
VGAT activity also depends on Cl (Juge et al., 2009).
However, VGAT-mediated GABA uptake was actually accompa-
nied by active Cl flux (Figures 2 and 4F; Juge et al., 2009) and
was insensitive to acetoacetate up to at least 5 mM
(Figure 4E). VMAT2 is a DpH-driven monoamine transporter
(Schuldiner, 1994). The DpH-driven serotonin uptake by partially
purified VMAT2 was found to be entirely independent of Cl and
acetoacetate (Figures 4D and 4E). No Cl uptake by VMAT2 was
observed (Figure 4F).monitored. Proteoliposomes containing either VGAT or the E213A mutant
VGAT were also measured. Additions: KCl, 10 mM; GABA, 5 mM; glutamate,
5 mM; glycine, 5 mM; Val, 2 mM; nystatin, 250 mM. A principle of assay system
was also illustrated. See also Figure S2.
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Figure 3. Acetoacetate Is a Physiological Modulator of VGLUT2 through Competition with Cl–
(A) Dose-dependent inhibition of VGLUT2 by various compounds as indicated in the presence of 10 mM Cl. For results of other substances, see Figure S4.
Glutamate uptake at 1 min is shown. Error bars represent mean ± SEM; n = 3. See also Figure S3 and S4.
(B) Acetoacetate did not affect Dc. Val-evoked formation of Dc in the absence or presence of 10 mM acetoacetate. Error bars represent mean ± SEM; n = 3.
(C) Glutamate uptake at 1 min at various [Cl] in the presence of the indicated concentrations of acetoacetate. Glutamate uptake in the absence of acetoacetate
(Figure 1D) was also shown as a dashed line for comparison. Error bars represent mean ± SEM; n = 3.
(D) Hill plot of glutamate uptake at the indicated concentrations of acetoacetate. Data were taken from Figure 3C.
(E) Eadie-Hofstee plot of glutamate uptake in the presence or absence of 0.2 mM acetoacetate.
(F) Inhibition caused by 5 mM acetoacetate was fully reversed by washing the proteoliposomes. Error bars represent mean ± SEM; n = 3.
(G) Protection of glutamate uptake activity by Cl or acetoacetate against DIDS inactivation. Proteoliposomeswere incubated in the absence or presence of 1 mM
DIDS (DIDS-treated VGLUT2) and in two cases, in the presence of 5mMacetoacetate (acetoacetate andDIDS treated VGLUT2) for 1min. These proteoliposomes
were then incubated in buffer containing 10 or 100mMCl in the presence or absence of DIDS. After 1 min, Val-evoked uptake of glutamate wasmeasured. Error
bars represent mean ± SEM; n = 3.
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Metabolic Control of Excitatory NeurotransmissionAcetoacetate Modulates Vesicular Glutamate Release
The fact that ketone bodies, in particular acetoacetate, modulate
VGLUTs activity raises the possibility that ketone bodies modu-
late glutamatergic neurotransmission in vivo.We therefore inves-
tigated the effect of acetoacetate on vesicular storage and
subsequent exocytotic release of glutamate.
The effect of acetoacetate on the exocytosis of glutamate from
neurons and astrocytes derived from hippocampus was studied
first. Upon stimulation with 50 mM KCl, appreciable amounts of
glutamate were released from neurons (Figure 5A). Acetoacetate
inhibited glutamate exocytosis when added to culturemedium atconcentrations above 0.5 mM (Figure 5A). Maximum inhibition
was observed at 1 mM acetoacetate. The inhibition was fully
reversed by removal of acetoacetate from the culture medium
(Figure 5A). Astrocytes also express VGLUT and are thus
capable of storing glutamate in synaptic-like microvesicles and
secreting it through exocytosis (Bezzi et al., 2004). Upon KCl
stimulation, glutamate (19.8 ± 0.3 nmol/20 min/mg protein) was
released from astrocytes. However, glutamate release was not
affected by 5 mM acetoacetate (Figure 5B). Thus, acetoacetate
reversibly inhibits glutamate exocytosis in neurons but not in
astrocytes.Neuron 68, 99–112, October 7, 2010 ª2010 Elsevier Inc. 103
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Figure 4. Cl– Dependence and Its Modula-
tion by Acetoacetate Is a Specific Property
of SLC17 Vesicular Neurotransmitter Trans-
porters
(A) Val-evoked uptake of glutamate (0.1 mM) by
purified, reconstituted VGLUT1 was assayed.
(Left) Coomassie brilliant blue-stained SDS gel of
reconstituted proteoliposomes (10 mg protein
each) showing the purified transporters. (Center)
time course in buffer containing 10mMCl (closed
circles). (Right) Val-evoked glutamate uptake at
1 min in the presence or absence of the indicated
concentration of Cl.
(B–D) Purification, time course, and Cl depen-
dence of VGLUT3 (B), VEAT (C), and VMAT2 (D).
Glutamate (0.1 mM) and aspartate (0.1 mM) were
used as substrates for VGLUT3 and VEAT, respec-
tively. In the case of VMAT2, DpH-dependent
uptake of serotonin (10 mM) was measured by
the pH jump method. See also Figure S5.
(E) The effect of acetoacetate in the presence of
10mMCl. In ‘‘washout’’ experiments, the proteo-
liposomes were washed with buffer lacking
acetoacetate after incubation in 5 mM acetoace-
tate. Full activity (100%) of VNUT and VGAT was
16.0 ± 3.2 and 6.9 ± 1.0 nmol/min/mg protein,
respectively. Full activity of VGLUT1, VGLUT3,
VEAT, and VMAT2 was as indicated above. Error
bars represent mean ± SEM; n = 3. See also
Figure S6.
(F) 36Cl uptake at 1min during the uptake of trans-
port substrates by the respective transporters.
Error bars represent mean ± SEM; n = 3.
Neuron
Metabolic Control of Excitatory NeurotransmissionThe effect of acetoacetate on quantal glutamate release was
monitored by recording miniature excitatory postsynaptic
currents (mEPSCs) from CA1 pyramidal cells in acute mouse104 Neuron 68, 99–112, October 7, 2010 ª2010 Elsevier Inc.hippocampal slices (Figure 6). The
average amplitude of mEPSCs in slices
with 10 mM acetoacetate (6.88 ±
0.69 pA; n = 15) was significantly smaller
than in control slices (9.03 ± 1.23 pA;
n = 15), reflecting a reduction in quantal
size (Figure 6A). Acetoacetate also
reduced the frequency of mEPSCs
induced by hypertonic sucrose (Fig-
ure 6B), suggesting either a reduced like-
lihood of release or merely an increased
proportion of events falling below the
detection threshold of 4 pA. However,
there was no effect of acetoacetate on
the paired-pulse ratio (Figure 6C), indi-
cating no change in the probability of
release. Interestingly, acetoacetate treat-
ment resulted in a reduction in the AM-
PA:NMDA EPSC ratio (Figure 6D) sug-
gesting that the synaptic glutamate
concentration is nonsaturating at AMPA
receptors, a conclusion supported by
other observations (J.A.G. and R.A.N.,unpublished data). In addition, acetoacetate had no effect on
the amplitude or frequency of miniature inhibitory postsynaptic
currents (mIPSCs) (Figure S8). Taken together, these results
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Figure 5. Acetoacetate Modulates Vesic-
ular Glutamate Release from Neurons but
Not from Astrocytes
(A) Cultured hippocampal neurons were treated
with the indicated concentrations of acetoacetate
20 min before KCl stimulation. For the ‘‘washout’’
experiment, acetoacetate-treated cells were
washed with medium and incubated a further
1 hr. KCl-dependent glutamate release was as-
sessed for 20 min. Error bars represent mean ±
SEM; n = 6.
(B) Hippocampal astrocytes were also treated with
5 mM acetoacetate. Glutamate secretion upon the
addition of KCl was measured as described
above. Error bars represent mean ± SEM; n = 6;
asterisks indicate statistical significance,
***p < 0.001.
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Metabolic Control of Excitatory Neurotransmissionare consistent with the idea that acetoacetate suppresses the
amount of glutamate stored per synaptic vesicle.
Acetoacetate-Mediated Seizure Control
As the ability of acetoacetate to inhibit VGLUTs and transmitter
release suggests that this may account for its anticonvulsant
activity. (Freeman et al., 2006; Hartman et al., 2007). We there-
fore examined the effect of acetoacetate on 4-aminopyridine
(4AP)-evoked glutamate secretion and seizures in the rat. 4AP
is a K+-channel blocker with convulsant activity (Pen˜a and Tapia,
2000) and was introduced through a micropipette directly into
the rat brain. Extracellular levels of glutamate were monitored
before, during andafter the seizures, usingdopamine as a control
(Figure 7A). Administration of 4AP evoked seizures (Figure 7B)
and led to the concomitant secretion of glutamate and dopamine
as previously reported (Figures 7A and 7C; Pen˜a and Tapia,
2000). Acetoacetate reduced the intensity of 4AP-evoked
seizures (Figure 7B) and also decreased glutamate release in
a dose-dependent manner (Figures 7C and 7D). In contrast, ace-
toacetate did not affect 4-AP-evoked dopamine secretion at all
(Figures 7C and 7D). After removing acetoacetate from the dial-
ysis solution, the intensity of 4AP-evoked seizures again
increased (Figure 7B). The levels of glutamate secretion also
partially recovered (Figures 7C and 7D).
DISCUSSION
Mechanism of Cl– Dependence
The use of proteoliposomes containing purified VGLUT protein
enabled us to separate the energetic coupling between primary
proton pump and VGLUT and to assess directly the interaction of
Cl with VGLUT. Using this assay, we presented evidence that
extravesicular Cl is absolutely necessary for glutamate trans-
port and acts as an allosteric effector. Strong positive coopera-
tivity (3) suggested that VGLUT-mediated glutamate transport
is tightly regulated through Cl. No active Cl transport occurs
during Dc and Cl-mediated glutamate transport through
VGLUT. The rate of glutamate uptake is not affected by Cl
concentrations above 5 mM, indicating clearly that the decline
in glutamate uptake by synaptic vesicles or proteoliposomes
containing VGLUT and F-ATPase observed at higher Cl
concentrations in previous work (Naito and Ueda, 1985; Mor-iyama and Yamamoto, 1995; Juge et al., 2006; Schenck et al.,
2009) is due to a secondary effect of the primary proton pump
rather than VGLUT. Moreover, these results refute the possibility
that the decline in uptake at Cl concentrations above 10 mM
results from competition with glutamate as recently proposed
(Schenck et al., 2009). In further contrast to this report, we did
not observe any stimulatory effect of intravesicular Cl. At the
present, this discrepancy is hard to explain. One possible expla-
nation is that intravesicular Cl activates the F-ATPase and
thereby increases Dc and extravesicular Cl leaking from the
lumen facilitates glutamate uptake. Such activation by internal
Cl has been observed for the V-ATPase (Moriyama and Nelson,
1987a, 1987b).
We found that DIDS competes with Cl. We also found that
ketone bodies reversibly inhibited VGLUT2 through competition
with Cl andDIDS. These results suggested that Cl and acetoa-
cetate share the same binding site on VGLUT2 and that the
occupation of this site by either Cl or acetoacetate determines
the activity status of VGLUT2, although a possibility that they
bind at different sites that interact allosterically cannot be
extruded. It is noteworthy that essentially the same results
were observed with isolated synaptic vesicles (Figure S5), sup-
porting the presence of extravesicular binding site(s) for Cl
and ketone bodies on VGLUT2. We further demonstrated that
not only VGLUTs but also VNUT and VEAT exhibited similar
Cl dependence and lack of Cl transport. NPT1, the first iden-
tified member of SLC17 transporter family, also exhibits similar
Cl dependence (Iharada et al., 2010). Furthermore, we recently
found that SLC17 transporters in Drosophila melanogaster also
retain similar Cl dependence and lack of Cl transport (T. Miyaji,
B. Laridon, B. Dermaut, H.O., and Y.M., unpublished data). Thus,
the use of Cl as an allosteric effector reflects a common mech-
anism for SLC17-type anion transporters.
At present, we are not able to identify the precise location of
the putative Cl binding site(s) on VGLUT2. Based on the 3D
structure of the bacterial glycerol-3-phosphate transporter, we
have proposed a structural model of VGLUT2 in which the amino
acid residues essential for glutamate transport, Arg184, His128,
and Glu191 are located close to the bottom of the protein (Juge
et al., 2006; Almqvist et al., 2007). We assume that basic amino
acid residue(s) in this area of the molecule are important for Cl
binding and are now trying to identify the putative Cl bindingNeuron 68, 99–112, October 7, 2010 ª2010 Elsevier Inc. 105
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Figure 6. Acetoacetate Reduces Quantum Glutamate Release
Whole-cell voltage clamp recordings from CA1 pyramidal neurons in acute mouse hippocampal slices incubated in either 10 mM LiCl or 10 mM lithium acetoa-
cetate for >2 hr.
(A) mEPSC amplitude is significantly reduced following incubation with acetoacetate. Cumulative distribution and average mEPSC amplitudes (n = 15) represen-
tative averaged traces; scale bars, 2 pA, 10 ms.
(B) mEPSC frequency is significantly reduced following incubation with acetoacetate. Cumulative distribution of mEPSC inter-event intervals (n = 15), average
mEPSC frequency, and sample traces; scale bars, 10 pA, 2 s.
(C) Paired-pulse ratio (PPR) is unchanged (n = 16). Average PPR and representative traces; scale bars, 20 pA, 15 ms.
(D) AMPA:NMDA EPSC ratio is significantly reduced (n = 16). Average ratio and representative traces; scale bars, 40 pA, 20 ms. Error bars = mean ± SEM; aster-
isks indicate statistical significance, **p < 0.01.
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Metabolic Control of Excitatory Neurotransmissionsite(s) by extensive chemical modification combined with site-
directed mutagenesis.
Metabolic Control of Glutamate Release
The unusually strong cooperativity of Cl activation (3) makes
it possible for small changes in cytoplasmic [Cl] to influence106 Neuron 68, 99–112, October 7, 2010 ª2010 Elsevier Inc.the activity of VGLUTs. When acetoacetate is present, the
Cl dependence of VGLUTs is modified and higher Cl concen-
trations are needed to maintain transport activity. The allosteric
regulation of VGLUTs by Cl functions as a switch to turn
vesicular storage on or off, and influences the subsequent
release of glutamate (Figure 8). Ketone bodies such as
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Figure 7. Acetoacetate Inhibited 4AP-Evoked
Seizures and Glutamate Secretion
(A) Schematic diagram and typical protocol of 4AP-evoked
seizures. At the times and duration indicated, 10 mM 4AP
was added. Acetoacetate (10 mM) was added during the
indicated period.
(B) 4AP-evoked seizures and the protective effect of
10 mM acetoacetate were observed for 1 hr after each
addition of 4AP and given a total seizure severity score
(TSSS) based on behavioral analysis. Error bars represent
mean ± SEM; n = 6. Asterisks indicate statistical signifi-
cance (Student’s t test), *p < 0.1, **p < 0.01, ***p < 0.001.
(C) Typical HPLC chromatogram of glutamate and dopa-
mine secreted at the indicated sampling times. *o-phos-
pho-L-serine at 40 pmol as an internal marker.
(D) Dose dependence of acetoacetate on 4AP-evoked
glutamate secretion.
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Metabolic Control of Excitatory Neurotransmissionacetoacetate act as physiological, reversible, and nontoxic
modulators for this switch. Under normal conditions, the switch
is continuously ‘‘on,’’ but when the concentration of ketone
bodies rises sufficiently, the switch is turned off. Ketone bodies
produced in the liver enter the circulatory system from which
they eventually permeate the blood-brain barrier through
a monocarboxylate transporter (MCT) and then serve as
substrates for energy production in neurons and/or astrocytes
(Figure S4; Laffel, 1999; Hartman et al., 2007; Freeman et al.,
2006). The blood level of ketone bodies of 10 mM upon either
fasting or ingestion of a ketogenic diet appears easily highNeuron 68, 99–112, October 7, 2010 ª2010 Elsevier Inc. 107t
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-
tenough to modulate VGLUTs function and
quantal glutamate release.
We found that this modulation of glutamate
release by ketone bodies occurs in vivo. When
applied to cultured neurons and sliced brain
tissues, acetoacetate effectively and reversibly
inhibited vesicular glutamate release. In addi-
tion, acetoacetate reduced quantal size as
measured bymEPSCs in sliceswithout affecting
mIPSCs. Furthermore, acetoacetate sup-
presses the seizures and glutamate release
evoked with 4AP. Since a ketogenic diet does
not affect free glutamate levels in the brain nor
the expression and activities of glutamate
receptors or plasma membrane glutamate
transporters, the present results support the
idea that the target of this acetoacetate-evoked
reduction in quantal size is VGLUT itself. It
should be stressed that there are several seizure
models and whether ketone bodies are effective
in models other than 4AP-evoked seizures
awaits further study.
It is noteworthy that acetoacetate-evoked
modulation isneuronspecific.Astrocytesareglu-
tamatergic in nature and secrete glutamate
through exocytosis of VGLUT-containing secre-
tory vesicles (Bezzi et al., 2004). Although all
VGLUT isoforms exhibit similar affinity to acetoa-
cetate, acetoacetate had no effect on vesicularglutamate release by astrocytes. At present, we do not know the
reason for the lack of effect in astrocytes, but it is possible tha
ketone bodies are transported with different efficiencies due to
the different transporters expressed in neurons and astrocytes
and that this may lead to different accessibilities of acetoacetate
to theCl-binding site on VGLUT.MCT is involved in themobiliza
tion of ketone bodies into the brain. The isoform MCT2 is ex
pressed in neurons, while isoforms MCT1 and MCT4 are presen
in astrocytes (Bergersen et al., 2002; Debernardi et al., 2003).
Since ketone bodies are metabolic intermediates connecting
fatty acid oxidation, glycolysis, and the TCA cycle, metabolic
Signal transmission
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Ketogenic diet
Ketone bodies
Glutamate
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Figure 8. Proposed Mode of Action of Ketone Bodies on VGLUT-
Mediated Suppression of Glutamatergic Neurotransmission
(A) The activity state of VGLUT is strongly dependent on the positive cooper-
ativity of Cl binding. Acetoacetate may replace Cl, which may lead to inac-
tivation of VGLUT, causing suppression of vesicular glutamate release.
(B) The concentration of circulating ketone bodies (acetoacetate) increases
upon ketosis and can effectively suppress VGLUT activity leading to a shut
down in excitatory neurotransmission. Once the state of ketosis is ended,
for instance by eating carbohydrates, this suppression is readily released
and excitatory neurotransmission recovers.
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Metabolic Control of Excitatory Neurotransmissionstate may control glutamatergic neurotransmission by switch-
ing the VGLUTs between active and inactive states (Figure 8).
Thus, the metabolic control of vesicular glutamate release
explains at least in part how ketone bodies help to control
epilepsy. This mechanism also explains at least in part how
ketone bodies exert neuroprotective effect (Zhao et al., 2006;
Gasior et al., 2006; Hartman et al., 2007). It is well known that
disruption of ketosis by the ingestion of sweets (carbohydrates)
negatively and acutely affects the therapeutic efficacy of the
ketogenic diet, but the mechanism remains unknown (Freeman
et al., 2006). According to our model (Figure 8B), this phenom-
enon can be explained as follows: fasting and ketogenic diets
cause ketosis, which in turn suppresses glutamatergic neuro-
transmission through the inhibition of vesicular glutamate
storage. The ingestion of carbohydrates decreases levels of
acetoacetate, which quickly turns VGLUT activity on, leading
to an influx of glutamate into synaptic vesicles, and the restora-
tion of glutamatergic neurotransmission. Thus, sugar-depen-
dent breakdown of the therapeutic effect by the ketogenic108 Neuron 68, 99–112, October 7, 2010 ª2010 Elsevier Inc.diet may be consequence of metabolic control of vesicular
release.
The switching of VGLUTs may also occur in pathological
conditions, for example the maple syrup urine disease, a genetic
disorder affecting the branched chain keto acid dehydrogenase
complex. Toxic metabolites such as a-ketoisovaleric acid,
a-keto-b-methylvaleric acid, and a-ketoisocaproic acid accu-
mulate and cause various neurological dysfunction. These
compounds inhibit ATP-dependent glutamate uptake into iso-
lated synaptic vesicles (Reis et al., 2000) and modulate Cl-
dependence of VGLUTs (Figure S3). Loss of vesicular glutamate
release may be at least partly responsible for the various mental
symptoms observed in these patients.
Conclusions and Perspectives
The results show that anion-dependent switching of VGLUT
activity plays a key role in the metabolic control of vesicular
glutamate release. Cl acts as an allosteric activator of VGLUT
and triggers glutamate uptake upon binding. Ketone bodies
compete for the putative Cl binding site(s) and turn VGLUT
activity off upon binding, causing a reduction in glutamatergic
neurotransmission in vivo. The identification of ketone bodies
as physiological modulators of VGLUTs opens the path for novel
approaches in the development of drugs to treat neurological
disorders caused by excessive glutamatergic neurotransmis-
sion. Drugs that interact with the putative Cl binding site(s)
would be expected to suppress excitatory neurotransmission.
Elucidation of the molecular mechanism for allosteric regulation
by Cl and ketone bodies would greatly contribute to the under-
standing of the SLC17 family transport mechanism, since the
switching regulatory mechanism is conserved among all
members, raising the possibility that purinergic and aspartergic
neurotransmission could be also regulated by ketone bodies.
EXPERIMENTAL PROCEDURES
Expression of VGLUT2
Recombinant baculovirus containing rat VGLUT2 was described elsewhere
(Juge et al., 2006). Recombinant baculovirus was constructed using the
Bac-to-Bac baculovirus expression system (Invitrogen) according to the
manufacturer’s protocol. Briefly, cDNA was cloned into the pDEST10 vector
to generate genes for N-terminal 63 His-tag fusion proteins. DH10Bac cells
carrying bacmid DNA were transformed with the resulting pDEST10 vector
and recombinant bacmid was isolated from clones of these cells. Recombi-
nant baculoviruses were obtained by infection of Sf9 cells with bacmid. High
Five cells (5 3 106 cells/10 cm dish) were grown in Express Five medium
(GIBCO) supplemented with 2 mM L-glutamine and 10 mg/ml gentamycin at
27C. High Five cells were infected with recombinant baculoviruses at a multi-
plicity of infection of 2 and grown for an additional 48 hr.
Purification of VGLUT2
VGLUT2 was purified as described previously (Juge et al., 2006). Insect cells
(12 3 108 cells) were suspended in buffer containing 20 mM Tris-HCl
(pH 8.0), 0.1 M potassium acetate, 10% glycerol, 0.5 mM dithiothreitol,
1 mg/ml pepstatin A, and 1 mg/ml leupeptin and disrupted by sonication with
a TOMY UD200 tip sonifier. Cell lysates were centrifuged at 700 3 g for
10 min to remove debris and the resultant supernatant was centrifuged at
160,000 3 g for 1 hr. The pellet (membrane fraction) was suspended in buffer
containing 20 mMMOPS-Tris (pH 7.0), 10% glycerol, 1 mg/ml pepstatin A, and
1 mg/ml leupeptin at approximately 3 mg protein/ml. The membrane fraction
was solubilized with 2% octylglucoside. After centrifugation at 260,000 3 g
Neuron
Metabolic Control of Excitatory Neurotransmissionfor 30 min, the supernatant was added to 1 ml of Ni-NTA Superflow resin
(QIAGEN) and incubated for 4 hr at 4C. The resin was washed with 10 ml of
20mMMOPS-Tris (pH 7.0), 5 mM imidazole, 20%glycerol and 1%octylgluco-
side in a column. VGLUT2 was eluted from the resin with 3 ml of the same
buffer containing 60 mM imidazole. The eluate containing purified VGLUT2
was stored at 80C where it was stable without loss of activity for at least
a few months.
Reconstitution of VGLUT2
Reconstitution of purified recombinant VGLUT2 into liposomes was carried
out by the freeze-thaw method described elsewhere (Juge et al., 2006).
In brief, 10 mg VGLUT2 was mixed with 500 mg liposomes, frozen at 80C,
and left at this temperature for 15 min. The mixture was thawed quickly by
holding the sample tube in the hand and diluted 60-fold with reconstitution
buffer (20 mM MOPS-Tris (pH 7.0), 0.5 mM dithiothreitol, 0.15 M sodium
acetate, and 5 mMmagnesium acetate). The buffer composition was changed
as necessary. Reconstituted proteoliposomes were pelleted by centrifugation
at 200,000 3 g for 1 hr at 4C and suspended in 0.2 ml of 20 mM MOPS-Tris
(pH 7.0) containing 0.15 M sodium acetate and 5 mM magnesium acetate.
Asolectin liposomes were prepared as follows: soybean lecithin (20mg; Sigma
type IIS) was suspended in 2 ml of 20 mM MOPS-NaOH (pH 7.0) containing
1 mM dithiothreitol. The mixture was sonicated in a bath-type sonicator until
clear, divided into small aliquots, and stored at 80C until use.
Expression, Purification, and Reconstitution of VGLUT1, VGLUT3,
VNUT, VGAT, and VMAT2
The cDNAs of rat VGLUT1, human VGLUT3, human VNUT, mouse VEAT, rat
VGAT, and rat VMAT2 have been described previously (Bellocchio et al.,
2000; Takamori et al., 2002; Sawada et al., 2008; Miyaji et al., 2008; Juge
et al., 2009; Liu et al., 1992). These transporters were expressed in insect cells,
purified, reconstituted into proteoliposomes, and assayed in a manner analo-
gous to that described for rat VGLUT2 above.
Uptake of Neurotransmitters
Assays were carried out by the gel-permeation procedure as described previ-
ously (Juge et al., 2006). For Val-evoked glutamate uptake, a 500 ml of reaction
mixture containing 20 mM MOPS-Tris (pH 7.0), 5 mM magnesium acetate,
10 mM KCl, 0.14 M potassium acetate, 2 mMVal, and 100 mM [2,3-3H] L-gluta-
mate (0.5 MBq/mmol, GE Health Care) was incubated for 3 min at 27C. Pro-
teoliposomes containing VGLUT2 (0.5 mg protein per assay) were added to
the mixture to initiate the reaction and incubated for a further 1 min. Aliquots
(130 ml) were taken at the times indicated and centrifuged through a Sephadex
G-50 (fine) spin column at 760 3 g for 2 min. Radioactivity in the eluate was
counted by liquid scintillation.
Essentially the same protocol was used for the Val-evoked uptake of aspar-
tate and ATP. The assay mixture containing 100 mM [2,3-3H] aspartate
(0.5 MBq/mmol) or 100 mM [a32P] ATP (3.7 MBq/mmol) was used instead of
glutamate. For serotonin uptake by VMAT2, proteoliposomes were prepared
as described above except for 20 mMMES-Tris (pH 5.5) was used. The assay
was initiated by addition of proteoliposomes to assay mixture containing
20 mM MOPS-Tris (pH 7.0), 5 mM magnesium acetate, 10 mM KCl, 0.14 M
potassium acetate, 10 mM [2-3H] serotonin (0.5 MBq/mmol) and incubated
for a further 1 min at 27C. Aliquots (130 ml) were taken at the times indicated
and centrifuged through a Sephadex G-50 (fine) spin column. Radioactivity of
the eluate were measured.
Cl– Transport
For Cl transport, a 500 ml reaction mixture containing 20 mM MOPS-Tris
(pH 7.0), 5 mM magnesium acetate, 5 mM glutamate, 0.14 M potassium
acetate, 2 mM Val and 10 mM radioactive 36Cl (740 MBq/g, ARC) was prein-
cubated for 3min at 27C. Reactions were started by adding the VGLUT2-con-
taining proteoliposomes (0.5 mg protein per assay) and incubated for a further
1 min. Aliquots (130 ml) were taken at the indicated times and passed through
a spin column as described above. Essentially the same protocol was used for
Cl transport by VGAT-containing proteoliposomes instead that GABA at
5mMwas included in the assaymixture (Juge et al., 2009). Nystatin was addedto a final concentration of 250 mM to determine internal [Cl] after equilibrium of
Cl was established across the proteoliposomal membrane.
Cl transport was also monitored by SPQ fluorescence with excitation (Ex)
and emission (Em) wavelengths of 344 nm and 443 nm, respectively, with
a path length of 5 nm (Biwersi et al., 1994). The assay was carried out at
27C in 2 ml 20 mM MOPS-Tris (pH 7.0), 5 mM magnesium acetate, 10 mM
KCl, 0.15M potassium acetate, and proteoliposomes containing 1 mg VGLUT2
or VGAT.
Measurement of Dc
Dc was measured by both fluorescence quenching of oxonol-V, as described
(Juge et al., 2006) and radioisotope distribution (Juge et al., 2009). Proteolipo-
somes were incubated under standard assay conditions in the presence of
20 mM [14C] potassium SCN for 3 min, and the internal concentration of
[14C]SCN was quantified as described. The internal volume of proteolipo-
somes was determined by measuring the exclusive volume with [14C]mannitol
(Juge et al., 2006). Dc was then calculated using following formula: Dc =
RT/F 3 ln{[internal SCN ]/[external SCN]}, R; gas constant, T; absolute
temperature, F; Faraday constant.
Cell Culture and Isolation of Neurons and Astrocytes
Rat fetal hippocampal neurons were isolated and cultured as described in
a previously published report (Banker and Cowan, 1977). After isolation, the
hippocampus was incubated in Hank’s solution containing 0.25% trypsin,
0.01% DNase1 for 15 min at 37C. The cells were washed twice with DMEM
and cultured at 4.0 3 105 cells/3.5 cm dish in Neurobasal medium (GIBCO)
supplemented with 0.5 mM glutamine, 100 units/ml penicillin, 100 mg/ml strep-
tomycin, 0.25 mg/ml fungizone, and B27 supplement (GIBCO). Hippocampal
astrocytes were isolated using a procedure similar to that used for neurons,
cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine
serum in 5% CO2/95% air at 37
C.
Determination of L-Glutamate and Dopamine
Cultured cells (4.0 3 106 cells/dish) were washed three times with Ringer’s
solution containing 128 mM NaCl, 1.9 mM KCl, 1.2mM KH2PO4, 2.4 mM
CaCl2, 1.3 mM MgSO4, 26 mM NaHCO3, 10 mM glucose, 0.2% BSA,
10 mM HEPES-Tris (pH 7.4) and then incubated in Ringer’s solution and inhib-
itor for 1 hr at 37C. The cultured cells were transferred to 2 ml of the above
Ringer’s solution containing KCl at the specified concentrations. At the times
indicated, samples (100 ml each) were taken and the amount of L-glutamate
was determined by high pressure liquid chromatography (HPLC) on aCOSMO-
SIL5 C18-ARII column (4.6 3 150 mm; Nacalai Tesque Inc.) and fluorescence
detected as described previously (Nakatsuka et al., 2001). Dopamine contents
weremeasured byHPLC combinedwith amperometric detection as described
previously (Nakatsuka et al., 2001).
Electrophysiology
Electrophysiological assessment was performed as described previously
(Elias et al., 2006). Briefly, transverse 300 mm hippocampal slices were cut
from C57BL/6 mice on a vibrating microtome (D.S.K microslicer DTK-1000,
Dosaka EM, Kyoto, Japan) in a solution containing 2.5 mM KCl, 0.5 mM
CaCl2, 7 mM MgCl2, 1.25 mM NaH2PO4, 25 mM NaHCO3, 7 mM glucose,
210 mM sucrose. Slices were recovered at 35C for 1 hr in artificial cerebro-
spinal fluid (ACSF) containing 110 mM NaCl, 2.5 mM KCl, 25 mM NaHCO3,
1 mM NaH2PO4, 10 mM glucose, 4 mM CaCl2, 4 mM MgCl2, and either
10 mM LiCl or 10 mM lithium acetoacetate, depending on experimental condi-
tion. Slices were then maintained for at least 1 hr at room temperature, slices
then transferred to a submersion chamber on an upright Olympusmicroscope,
perfused in ACSF saturated with 95%O2/5%CO2.Whole-cell recordings were
obtained with 3 to 5MU borosilicate glass pipettes filled with intracellular solu-
tion containing 135 mM CsMeSO4, 8 mM NaCl, 10 mM HEPES (pH 7.3),
0.3 mM EGTA, 5 mM QX-314-Cl, 0.3 mM NaGTP, 4 mM MgATP, and 290
mOsm. For mIPSC experiments, 135 mM CsCl replaced CsMeSO4. mEPSCs
were obtained at 70 mV in the presence of 0.5 mM TTX, 0.1 mM picrotoxin,
and 50 mM sucrose (to increase mEPSC frequency). mIPSCs were obtained
at70mV in the presence of 0.5 mMTTX, 10 mMNBQX, and 100 mMAPV.Mini-
ature currents were semiautomatically detected by offline analysis usingNeuron 68, 99–112, October 7, 2010 ª2010 Elsevier Inc. 109
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Metabolic Control of Excitatory Neurotransmissionin-house software in Igor Pro (Wavemetrics) with a detection threshold of 4 pA.
For evoked responses, Schaffer collaterals were stimulated with a bipolar
tungsten electrode at 0.1 Hz. Paired-pulse ratios were measured by giving
two pulses at a 50 ms interval and taking the ratio of the two peaks of the
EPSCs from an average of 40–50 sweeps. AMPA:NMDA ratios weremeasured
by dividing the peak EPSC current at70mV by the EPSC current 100ms after
stimulation at +40 mV. Series resistance wasmonitored and not compensated
and data from cells in which series resistance varied by >25%were discarded.
Synaptic responses were collected with a Multiclamp 700B amplifier (Axon
Instruments, Foster City, CA), filtered at 2 kHz and digitized at 10 Hz. For anal-
ysis of cumulative distributions, the D’Agostino-Pearson omnibus normality
test was used. For all other analyses an unpaired t test was used. All errors
bars represent standard error measurement.
Microdialysis
Microdialysis of rat brain hippocampus was carried out as previously
described (Funada and Hara, 2001). Adult Wistar rats weighing 220–250 g
each were group-housed under controlled conditions (24C with a 12 hr
light-dark cycle). All procedures were carried out in accordance with the
Guidelines for Animal Experiments at Okayama University. Rats were anesthe-
tized with ketamine (60 mg/kg) and xylazine (10 mg/kg) and mounted on the
stereotaxic frame. An intracranial guide (A-I-8, Eicom, Japan) was implanted
in the left hippocampus (5.2 mm caudal to bregma, 4.6 mm lateral to bregma,
and 4.6 mm ventral to dura) and was fixed to the skull with dental cement. The
cannula was closed by insertion of a stainless steel obturator. Twenty-four
hours after implantation of the guide cannula, A-I-8 microdialysis probes
were inserted into the hippocampus and then connected to a microinjection
pump at a rate of 2 ml/min. The probes were continuously perfused by micro-
dialysis with modified Ringer’s solution containing 147 mM NaCl, 2.3 mM
CaCl2, 4 mM KCl. Seizure was induced by delivering 4AP (10 mM) through
the microdialysis probe. Samples were collected every twenty minutes in
a fraction collector and then analyzed by HPLC.
Behavioral Assessment of Seizure Severity
Behavioral changes in each rat were recorded throughout the experiment.
During each sample the rats were rated on a previously published seizure
severity scale (Racine, 1972; Meurs et al., 2008) that corresponded to focal
limbic seizure models: (0) normal and nonepileptic activity; (1) mouth and facial
movements, hyperactivity, grooming, sniffing, scratching, and wet dog
snakes; (3) forelimb clonus, forelimb extension; (4) rearing, salivating, tonic-
clonic activity; (5) falling, status epilepticus.
Miscellaneous Procedures
Synaptic vesicles from the brain of rats (Wistar, male, about 200 gweight) were
prepared by the published procedurewithout the last permeation step (Huttner
et al., 1983). Transport assay by the synaptic vesicles, polyacrylamide gel
electrophoresis in the presence of SDS and western blotting were performed
as described (Moriyama and Yamamoto, 1995). Protein concentration was as-
sayed using bovine serum albumin as a standard (Schaffner and Weissmann,
1973).
Data Analysis
All numerical values are shown as themean ± SEM; n = 3–15, unless specified.
Statistical significance was determined by the Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures and can be found with this
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